Who Finances the First Factory?
The difficult passage from pilot line to industrial production
A working technology is not yet a financeable manufacturing business. In photonics, the decisive test is whether production can deliver consistent quality at a sustainable cost. ABN AMRO’s financing of XIVER shows how industrial expansion can attract bank lending. The harder question concerns the capital needed before that manufacturing record and customer base exist.
The first Signal examined the gap between research spending and industrial results. Here, the question becomes concrete: who pays while production is still becoming commercially reliable?
🟦 What remains unproven after a successful pilot?
A pilot can validate devices and manufacturing processes. Volume production must establish repeatability, delivery performance and margins.
In photonics, packaging, optical connections and reliability testing introduce further engineering demands. The Photonic Integration Technology Center identifies production yield and testing throughput as important scaling challenges.
Yield determines how many devices meet specifications; testing speed influences how economically they can be verified. Both affect the cost of each saleable product.
A design can therefore work while its production economics remain unviable. The financing hurdle is demonstrating that performance can survive repetition at a price customers accept.
🟦 Why can industrial progress deepen the cash gap?
Equipment commitments become binding before customer revenues are secure. Qualification delays extend that exposure while salaries, materials and operating costs continue.
The factory, customer and financier follow different timetables. Process development may require further iterations; the buyer may withhold volume orders until validation is complete; repayment obligations follow the agreed financing schedule.
An installed production line can consequently coexist with a working-capital shortage. Funding the equipment does not automatically fund the period needed to turn it into reliable commercial output.
Customer interest offers a market signal. Purchase volumes, cancellation rights and payment terms determine how much financial certainty follows.
🟦 What does the XIVER transaction actually prove?
On 1 October, ABN AMRO announced €28 million in senior debt financing for XIVER within a €55 million investment programme, including an ASML DUV lithography system.
XIVER already has manufacturing operations and international customers. It emerged from Philips and was acquired by Dutch investors in early 2025. The transaction supports expansion of that industrial base.
This is meaningful evidence that a commercial bank can finance European semiconductor and photonics-related capacity. It leaves the first-factory question open: how does a younger manufacturer finance the production record that lenders and customers want to see?
The announcement discloses neither detailed lending terms nor the full financing mix. It establishes bank participation, without revealing a model that can simply be transferred to an unproven production business.
🟦 When does the financing instrument become part of the problem?
Repayment obligations can outpace the development of commercial cash flow. A development grant may leave production working capital uncovered. Equity can absorb uncertainty, but investors must accept the capital required and the time before returns become possible.
The central problem is matching funding terms to the risks still unresolved.
The EIB’s venture-debt model illustrates one approach: debt designed to complement equity investment in innovative growth companies. Debt need not wait until every uncertainty disappears, but its structure must accommodate a credible route towards repayment.
Guarantees can share financial exposure. They cannot make an unreliable process deliver or turn tentative demand into firm orders. Financing needs to survive a plausible ramp-up, including delays and production losses.
🟦 Does the first factory have to belong to the scale-up?
A company using external manufacturers may need to finance access to production, packaging and testing rather than construct a dedicated plant. That shifts part of the investment burden to specialist suppliers; it does not remove it.
XIVER describes its role as helping customers develop repeatable manufacturing. Expanding such capacity can support several businesses alongside the factory owner.
The relevant industrial-policy test is therefore usable capacity: can companies obtain the processes, expertise and production slots they need?
That capacity also needs demand. Staged orders, customer contributions to qualification and credible volume commitments can help connect a supplier’s investment decision with a buyer’s requirements. Without that connection, additional equipment can become underused capacity.
Signal
A proven technology still needs reliable production, credible demand and enough capital to reach customer payment.
XIVER demonstrates that commercial lending can support industrial expansion. The harder financing problem comes earlier, when manufacturing performance and customer commitments are still being established.
Europe needs capital whose terms can withstand the uncertainty of early production — and customers willing to help turn that production into a market.
Who finances the work required to make the first factory bankable?
This is the second Signal in Altair Media Europe’s four-part series, From European Science to European Industry, examining who finances the journey from breakthrough research to industrial scale and practical use.
Image credit
AI-generated illustration by OpenAI for Altair Media Europe.
Caption
From working chip to reliable production: who finances the capacity, qualification and working capital needed to cross the industrial funding gap?
